Therapeutic outcome of spinal implant infections caused by Staphylococcus aureus A retrospective observational study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cho, Oh-Hyun | - |
dc.contributor.author | Bae, In-Gyu | - |
dc.contributor.author | Moon, Song Mi | - |
dc.contributor.author | Park, Seong Yeon | - |
dc.contributor.author | Kwak, Yee Gyung | - |
dc.contributor.author | Kim, Baek-Nam | - |
dc.contributor.author | Yu, Shi Nae | - |
dc.contributor.author | Jeon, Min Hyok | - |
dc.contributor.author | Kim, Tark | - |
dc.contributor.author | Choo, Eun Ju | - |
dc.contributor.author | Lee, Eun Jung | - |
dc.contributor.author | Kim, Tae Hyong | - |
dc.contributor.author | Choi, Seong-Ho | - |
dc.contributor.author | Chung, Jin-Won | - |
dc.contributor.author | Kang, Kyung-Chung | - |
dc.contributor.author | Lee, Jung Hee | - |
dc.contributor.author | Lee, Yu-Mi | - |
dc.contributor.author | Lee, Mi Suk | - |
dc.contributor.author | Park, Ki-Ho | - |
dc.date.available | 2020-02-27T09:41:02Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2018-10 | - |
dc.identifier.issn | 0025-7974 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/3275 | - |
dc.description.abstract | Spinal implant infection is a rare but significant complication of spinal fusion surgery, and the most common pathogen is Staphylococcus aureus. It is difficult to treat due to this pathogen's biofilm-forming ability and antibiotic resistance. We evaluated the therapeutic outcome of treatments for S aureus spinal implant infections. We retrospectively reviewed all patients with S aureus spinal implant infections at 11 tertiary-care hospitals over a 9-year period. Parameters predictive of treatment failure and recurrence were analyzed by Cox regression. Of the 102 patients with infections, 76 (75%) were caused by methicillin-resistant S aureus (MRSA) and 51 (50%) were late-onset infections. In all, 83 (81%) patients were managed by debridement, antibiotics, and implant retention (DAIR) and 19 (19%) had their implants removed. The median duration of all antibiotic therapies was 52 days. During a median follow-up period of 32 months, treatment failure occurred in 37 (36%) cases. The median time to treatment failure was 113 days, being <1 year in 30 (81%) patients. DAIR (adjusted hazard ratio [aHR], 6.27; P=.01) and MRSA infection (aHR, 4.07; P=.009) were independently associated with treatment failure. Rifampin-based combination treatments exhibited independent protective effects on recurrence (aHR, 0.23; P=.02). In conclusion, among patients with S aureus spinal implant infections, MRSA and DAIR were independent risk factors for treatment failure, and these risk factors were present in the majority of patients. In this difficult-to-treat population, the overall treatment failure rate was 36%; rifampin may improve the outcomes of patients with S aureus spinal implant infections. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | - |
dc.relation.isPartOf | MEDICINE | - |
dc.subject | HEMATOGENOUS VERTEBRAL OSTEOMYELITIS | - |
dc.subject | PROSTHETIC JOINT INFECTIONS | - |
dc.subject | RISK-FACTORS | - |
dc.subject | ANTIBIOTIC-TREATMENT | - |
dc.subject | RESISTANT | - |
dc.subject | COMBINATION | - |
dc.subject | VANCOMYCIN | - |
dc.subject | MANAGEMENT | - |
dc.subject | RIFAMPICIN | - |
dc.subject | FUSION | - |
dc.title | Therapeutic outcome of spinal implant infections caused by Staphylococcus aureus A retrospective observational study | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000452230500051 | - |
dc.identifier.doi | 10.1097/MD.0000000000012629 | - |
dc.identifier.bibliographicCitation | MEDICINE, v.97, no.40 | - |
dc.identifier.scopusid | 2-s2.0-85054449616 | - |
dc.citation.title | MEDICINE | - |
dc.citation.volume | 97 | - |
dc.citation.number | 40 | - |
dc.contributor.affiliatedAuthor | Moon, Song Mi | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | instrumentation | - |
dc.subject.keywordAuthor | outcome | - |
dc.subject.keywordAuthor | rifampin | - |
dc.subject.keywordAuthor | spondylitis | - |
dc.subject.keywordAuthor | treatment | - |
dc.subject.keywordAuthor | vertebral osteomyelitis | - |
dc.subject.keywordPlus | HEMATOGENOUS VERTEBRAL OSTEOMYELITIS | - |
dc.subject.keywordPlus | PROSTHETIC JOINT INFECTIONS | - |
dc.subject.keywordPlus | RISK-FACTORS | - |
dc.subject.keywordPlus | ANTIBIOTIC-TREATMENT | - |
dc.subject.keywordPlus | RESISTANT | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | VANCOMYCIN | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | RIFAMPICIN | - |
dc.subject.keywordPlus | FUSION | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.